Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
GW 8510 is an inhibitor of cyclin-dependent kinase 2 (Cdk2) and Cdk5 (IC50s = 3, 3, and 7 nM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk5/p25 complexes, respectively).1 It is selective for Cdk2 and Cdk5 over Cdk1/cyclin B, Cdk4/cyclin D, Cdk7/cyclin H, and Cdk9/cyclin T (IC50s = 49, 139, 317, and 543 nM, respectively). It also decreases ribonucleoside-diphosphate reductase subunit M2 (RRM2) levels and induces autophagy in HCT116 colon cancer cells when used at a concentration of 4 µM.2 GW 8510 (1-500 nM) protects against MPP+-induced cytotoxicity in primary human neural progenitor cells derived from induced pluripotent stem cells (iPSCs) in an in vitro model of Parkinson’s disease.3 In vivo, GW 8510 (2 mg/kg) increases grip strength and gastrocnemius and soleus muscle-to-body weight ratios in a mouse model of muscle atrophy induced by sciatic nerve denervation.4
WARNING This product is not for human or veterinary use.
1. How selective are pharmacological inhibitors of cell-
2. Repositioning of a cyclin-
3. Gene expression-
4. GW8510 alleviates muscle atrophy and skeletal muscle dysfunction in mice through AMPK/PGC1α signaling. Int. J. Mol. Med. 56(3), 128 (2025).